PL1817276T3 - Inhibitory katepsyny - proteazy cysteinowej - Google Patents

Inhibitory katepsyny - proteazy cysteinowej

Info

Publication number
PL1817276T3
PL1817276T3 PL05808098T PL05808098T PL1817276T3 PL 1817276 T3 PL1817276 T3 PL 1817276T3 PL 05808098 T PL05808098 T PL 05808098T PL 05808098 T PL05808098 T PL 05808098T PL 1817276 T3 PL1817276 T3 PL 1817276T3
Authority
PL
Poland
Prior art keywords
protease inhibitors
cysteine protease
cathepsin cysteine
cathepsin
inhibitors
Prior art date
Application number
PL05808098T
Other languages
English (en)
Inventor
Jacques Yves Gauthier
Chun Sing Li
Christophe Mellon
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of PL1817276T3 publication Critical patent/PL1817276T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL05808098T 2004-11-23 2005-11-18 Inhibitory katepsyny - proteazy cysteinowej PL1817276T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63040504P 2004-11-23 2004-11-23
EP05808098A EP1817276B1 (en) 2004-11-23 2005-11-18 Cathepsin cysteine protease inhibitors
PCT/CA2005/001764 WO2006056047A1 (en) 2004-11-23 2005-11-18 Cathepsin cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
PL1817276T3 true PL1817276T3 (pl) 2012-12-31

Family

ID=36497694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05808098T PL1817276T3 (pl) 2004-11-23 2005-11-18 Inhibitory katepsyny - proteazy cysteinowej

Country Status (24)

Country Link
US (2) US20070293578A1 (pl)
EP (1) EP1817276B1 (pl)
JP (1) JP5055488B2 (pl)
KR (1) KR20070085435A (pl)
CN (2) CN101061093A (pl)
AR (1) AR055283A1 (pl)
AU (1) AU2005309267B2 (pl)
BR (1) BRPI0518054A (pl)
CA (1) CA2589085C (pl)
DK (1) DK1817276T3 (pl)
ES (1) ES2394618T3 (pl)
IL (1) IL183308A (pl)
MX (1) MX2007006136A (pl)
MY (1) MY137717A (pl)
NO (1) NO339125B1 (pl)
NZ (1) NZ554872A (pl)
PE (1) PE20061054A1 (pl)
PL (1) PL1817276T3 (pl)
PT (1) PT1817276E (pl)
RU (1) RU2399613C2 (pl)
SI (1) SI1817276T1 (pl)
TW (1) TWI353244B (pl)
WO (1) WO2006056047A1 (pl)
ZA (1) ZA200703530B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308208B8 (pt) * 2002-03-05 2021-05-25 Axys Pharm Inc compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos
BRPI0410979A (pt) * 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
JP4988589B2 (ja) * 2004-12-01 2012-08-01 ビロベイ，インコーポレイティド システインプロテアーゼインヒビターとしてのハロアルキル含有化合物
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
EP1841419A4 (en) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSIN K AND OBESITY
JP2008531691A (ja) * 2005-03-02 2008-08-14 メルク エンド カムパニー インコーポレーテッド カテプシンｋ阻害組成物
EP1865940B1 (en) * 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
MX2007011739A (es) * 2005-03-22 2008-03-14 Celera Genomics Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
WO2008026953A1 (en) * 2006-08-28 2008-03-06 Akademia Medyczna Im. Piastow Slaskich We Wroclawiu A system and method for the extra-corporeal purification of blood of pathogenic enzymes
US20100048717A1 (en) * 2006-09-25 2010-02-25 MERCK FROSST CANADA LTD, Merk & Co., Inc. Cathepsin b inhibitors
MX2009003563A (es) * 2006-10-04 2009-04-15 Virobay Inc Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
US7893112B2 (en) * 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
WO2009065098A1 (en) * 2007-11-16 2009-05-22 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in the treatment of bone cancer
WO2010056877A2 (en) * 2008-11-13 2010-05-20 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
US8324417B2 (en) * 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
CN106916091B (zh) * 2015-12-24 2020-10-09 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) * 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
JP2021533121A (ja) 2018-08-02 2021-12-02 インターベット インターナショナル ベー． フェー． Ｎ１−（１−シアノシクロプロピル）−ｎ２−（１ｓ）−１−｛４’−［（１ｒ−２，２−ジフルオロ−１−ヒドロキシエチル］ビフェニル−４−イル｝−２，２，２−トリフルオロエチル）−４−フルオロ−ｌ−ロイシンアミドの結晶形態
AU2019312842A1 (en) 2018-08-02 2021-02-04 Intervet International B.V. Process to make a selective cathepsin cysteine protease inhibitor
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CN112438972B (zh) * 2019-08-29 2021-07-30 沈阳药科大学 组织蛋白酶抑制剂的医药用途
CN113462728B (zh) * 2021-07-09 2024-06-07 浙江工业大学 一种利用土星轮头酵母制备(r)-1-(4-溴苯基)-2,2,2-三氟乙醇的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273444C (zh) * 1997-11-05 2006-09-06 诺瓦提斯公司 二肽腈
JP4365094B2 (ja) * 2001-03-02 2009-11-18 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
US7302587B2 (en) * 2001-06-08 2007-11-27 Matra Transport International Secure computer system
US7371747B2 (en) * 2001-11-13 2008-05-13 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors
BRPI0308208B8 (pt) * 2002-03-05 2021-05-25 Axys Pharm Inc compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos
WO2004052921A1 (en) * 2002-12-05 2004-06-24 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
BRPI0410979A (pt) * 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
JP2008531691A (ja) * 2005-03-02 2008-08-14 メルク エンド カムパニー インコーポレーテッド カテプシンｋ阻害組成物

Also Published As

Publication number Publication date
AU2005309267A1 (en) 2006-06-01
RU2007123611A (ru) 2008-12-27
AR055283A1 (es) 2007-08-15
PE20061054A1 (es) 2006-10-20
MX2007006136A (es) 2007-07-19
IL183308A0 (en) 2007-09-20
DK1817276T3 (da) 2012-11-19
EP1817276A4 (en) 2009-12-09
US7407959B2 (en) 2008-08-05
US20060111440A1 (en) 2006-05-25
NZ554872A (en) 2010-12-24
WO2006056047A9 (en) 2007-06-21
TWI353244B (en) 2011-12-01
MY137717A (en) 2009-03-31
IL183308A (en) 2013-05-30
NO339125B1 (no) 2016-11-14
BRPI0518054A (pt) 2008-10-28
US20070293578A1 (en) 2007-12-20
NO20073222L (no) 2007-08-03
TW200631576A (en) 2006-09-16
KR20070085435A (ko) 2007-08-27
RU2399613C2 (ru) 2010-09-20
EP1817276A1 (en) 2007-08-15
CA2589085A1 (en) 2006-06-01
JP5055488B2 (ja) 2012-10-24
ZA200703530B (en) 2008-01-08
CN102391151A (zh) 2012-03-28
CN101061093A (zh) 2007-10-24
CA2589085C (en) 2014-04-29
ES2394618T3 (es) 2013-02-04
WO2006056047A1 (en) 2006-06-01
AU2005309267B2 (en) 2011-05-12
SI1817276T1 (sl) 2012-12-31
PT1817276E (pt) 2012-10-25
JP2008520590A (ja) 2008-06-19
EP1817276B1 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
IL183308A0 (en) Cathepsin cysteine protease inhibitors
HK1096956A1 (en) Cysteine protease inhibitors
ZA200710386B (en) Aspartyl protease inhibitors
IL187814A0 (en) Aspartyl protease inhibitors
HK1109151A1 (en) Aspartyl protease inhibitors
IL192134A0 (en) Soft protease inhibitors and pro-soft forms thereof
EP1694647A4 (en) INHIBITORS OF CYSTEINE PROTEASES OF THE CATHEPSIN TYPE
EP1981519A4 (en) PROTEASE INHIBITION
HK1121459A1 (en) Aspartic protease inhibitors
IL177055A0 (en) Silinae compounds as cysteine protease inhibitors
ZA200703102B (en) Processes and intermediates for preparing cysteine protease inhibitors
IL179056A0 (en) An hiv protease inhibitor
GB0513841D0 (en) Cysteine protease inhibitors
ZA200505418B (en) Cathepsin S inhibitors
EP1660436A4 (en) cathepsin inhibitors
HRP20130419T1 (en) Alpha ketoamide compounds as cysteine protease inhibitors
EP1673336A4 (en) INHIBITORS OF CATHEPSIN AND CYSTEINE PROTEASE
AP2007004079A0 (en) Hiv protease inhibitors
IL188850A0 (en) Cathepsin k inhibitors
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
EP1855672A4 (en) HIV PROTEASE INHIBITORS
EP1704142A4 (en) PROTEASE INHIBITORS
EP1706402A4 (en) INHIBITORS OF CATHEPSINE TYPE PROTEIN CYSTEINES
GB0513840D0 (en) Cysteine protease inhibitors
GB0513839D0 (en) Cysteine protease inhibitors